Aricept + IFN-alpha2A
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Memory Disorders
Conditions
Memory Disorders, Alzheimer's Disease
Trial Timeline
— → —
NCT ID
NCT00031018About Aricept + IFN-alpha2A
Aricept + IFN-alpha2A is a phase 2 stage product being developed by Pfizer for Memory Disorders. The current trial status is unknown. This product is registered under clinical trial identifier NCT00031018. Target conditions include Memory Disorders, Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00031018 | Phase 2 | UNKNOWN |
Competing Products
8 competing products in Memory Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 85 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 33 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 84 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| Piracetam | UCB | Pre-clinical | 20 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |